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AbsTrACT
Objective To determine whether exosomal microRNas 
(miRNas) in cerebrospinal fluid (csF) of patients with 
frontotemporal dementia (FTD) can serve as diagnostic 
biomarkers, we assessed miRNa expression in the 
Genetic Frontotemporal Dementia Initiative (GeNFI) 
cohort and in sporadic FTD.
Methods GeNFI participants were either carriers of 
a pathogenic mutation in progranulin, chromosome 
9 open reading frame 72 or microtubule-associated 
protein tau or were at risk of carrying a mutation 
because a first-degree relative was a known symptomatic 
mutation carrier. exosomes were isolated from csF of 23 
presymptomatic and 15 symptomatic mutation carriers 
and 11 healthy non-mutation carriers. expression of 752 
miRNas was measured using quantitative pcR (qpcR) 
arrays and validated by qpcR using individual primers. 
MiRNas found differentially expressed in symptomatic 
compared with presymptomatic mutation carriers were 
further evaluated in a cohort of 17 patients with sporadic 
FTD, 13 patients with sporadic alzheimer’s disease (aD) 
and 10 healthy controls (hcs) of similar age.
results In the GeNFI cohort, miR-204-5p and miR-632 
were significantly decreased in symptomatic compared 
with presymptomatic mutation carriers. Decrease of 
miR-204-5p and miR-632 revealed receiver operator 
characteristics with an area of 0.89 (90% cI 0.79 to 
0.98) and 0.81 (90% cI 0.68 to 0.93), respectively, 
and when combined an area of 0.93 (90% cI 0.87 to 
0.99). In sporadic FTD, only miR-632 was significantly 
decreased compared with aD and hcs. Decrease of miR-
632 revealed an area of 0.90 (90% cI 0.81 to 0.98).
Conclusions exosomal miR-204-5p and miR-632 have 
potential as diagnostic biomarkers for genetic FTD and 
miR-632 also for sporadic FTD.
InTrOduCTIOn
Frontotemporal dementia (FTD) is now recognised 
as the most common cause of early-onset dementia 
in people under the age of 60 years.1 FTD usually 
presents with either behavioural or language impair-
ment. The pathogenic mechanisms resulting in 
FTD remain largely unknown, but current knowl-
edge suggests that genetic, epigenetic and environ-
mental factors contribute to disease development.2 
Approximately 40% of patients with FTD have a 
positive family history of dementia3 and about 25% 
of patients with FTD have an identified genetic 
form of the disease.1 The vast majority of genetic 
FTD is inherited in an autosomal dominant pattern 
caused by mutations in one of three genes: chromo-
some 9 open reading frame 72 (C9orf72), progran-
ulin (GRN) or microtubule-associated protein 
tau (MAPT). These genes provide an opportunity 
to study the disease in its presymptomatic phase 
and offer great hope for elucidating the patho-
genic mechanisms that cause FTD. There is some 
mounting evidence that alterations in microRNA 
(miRNAs) may occur in FTD.4–6 MiRNAs are 
small, non-coding RNAs that regulate gene expres-
sion through post-transcriptional silencing of 
target mRNAs.7 The same miRNA may regulate 
hundreds of target mRNAs affecting complex 
disease pathways.8 MiRNAs are stable in body 
fluids and can be enriched in extracellular vesicles 
termed exosomes. These vesicles were thought to 
be a means for cells to discard unnecessary mole-
cules into the extracellular space,9 but more recent 
studies have shown that cells can transfer proteins, 
lipids, DNA, RNA and miRNA to other cells via 
exosomes.10 Exosomes display different miRNA 
profiles compared with serum and cells, suggesting 
that a specific selection of exosomal miRNAs 
provides signals to regulate pathways in recipient 
cells.11 This intercellular transfer can influence a 
multitude of biological processes relevant to the 
nervous system such as neuronal survival, neurite 
outgrowth and synaptic plasticity.12–15 Disease-rele-
vant miRNAs may be enriched within exosomes,16 
and since miRNA expression can vary in different 
disease states, exosomal miRNAs are attractive 
targets for biomarker profiling.17 18 
Genetic FTD is a rare condition, and single 
groups have only been able to study small numbers 
of patients. Through the Genetic Frontotemporal 
Dementia Initiative (GENFI), we obtained CSF 
from individuals who were either symptomatic or 
presymptomatic carriers of a known pathogenic 
mutation in GRN, MAPT or C9orf72 or who were 
non-affected first-degree relatives of a known symp-
tomatic carrier (healthy non-mutation carriers). 
We characterised miRNA expression profiles and 
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found miR-204-5p and miR-632 significantly decreased in 
symptomatic compared with presymptomatic mutation carriers, 
suggesting low miR-204-5p and miR-632 as potential diagnostic 
biomarkers. In a separate cohort, we found miR-632 significantly 
decreased in sporadic FTD compared with sporadic Alzheimer’s 
disease (AD) and healthy controls (HCs), highlighting its poten-
tial as a diagnostic biomarker for sporadic FTD.
MeThOds
ethics statements, sample collection and clinical data
Written informed consent and local research ethics boards’ 
approval was obtained. Six GENFI centres contributed CSF 
(Karolinska Institute, Department of Neurobiology, Stockholm, 
Sweden; Erasmus Medical Center, Department of Neurology, 
Rotterdam, The Netherlands; University College London, 
Dementia Research Centre, London, England; Université Laval, 
Département des Sciences Neurologiques, Quebec City, Canada; 
University of Milan, Centro Dino Ferrari, Fondazione Ca’ 
Granda IRCCS Ospedale Policlinico, Milan, Italy; and Univer-
sity of Toronto, Sunnybrook Health Sciences Centre, Toronto, 
Canada). The GENFI cohort consisted of 49 subjects: 38 
mutation carriers (22 GRN, 11 C9orf72 and 5 MAPT) and 11 
first-degree relatives who tested negative for a mutation in the 
gene that had been found mutated in their affected first-degree 
relative (healthy non-mutation carriers). Twenty-three mutation 
carriers were presymptomatic, and 15 mutation carriers were 
symptomatic. The clinical presentation was behavioural variant 
FTD (bvFTD) (n=12), non-fluent variant primary progressive 
aphasia (nfvPPA) (n=1), semantic variant primary progressive 
aphasia (svPPA) (n=1) or dementia not otherwise specified 
(D-NOS) (n=1) (online supplementary table 1). Mini-Mental 
State Examination (MMSE19) was carried out in all individuals. 
A cohort of sporadic FTD, sporadic AD and HCs was recruited 
at the University Health Network Memory Clinic, Toronto, and 
the University of California San Francisco Memory and Aging 
Center. This sporadic disease cohort consisted of bvFTD (n=7), 
bvFTD/amyotrophic lateral sclerosis (ALS) (n=4), svPPA (n=3), 
nfvPPA/ALS (n=1), svPPA/ALS (n=1), nfvPPA (n=1), sporadic 
AD (n=13) and HCs (n=10) (online supplementary table 2). 
BvFTD met the Rascovsky diagnostic criteria,20 PPA met the 
Gorno-Tempini diagnostic criteria,21 ALS met the El Esco-
rial diagnostic criteria22 and AD met the McKhann diagnostic 
criteria.23
samples for mirnA detection
Lumbar puncture was performed with a 20-gauge or 24-gauge 
spinal needle, and fluid was collected in polypropylene tubes 
according to local standards. Most sites follow ADNI procedures 
manual (http://www. adni- info. org/). CSF was stored in aliquots 
at −80°C until use.
real-time PCr
For the genetic cohort (n=49), 500 µL of each CSF sample was 
thawed and centrifuged at 10 000 × g for 5 min to pellet any 
debris. To isolate exosomes, the supernatant was transferred to 
a new reaction vial, and 200 µL precipitation buffer (miRCURY 
Exosome Isolation Kit, Exiqon, Copenhagen, Denmark) was 
mixed with the supernatant. The mix was incubated at 4°C for 
60 min and spun for 30 min at 10 000 × g at 20°C. The superna-
tant was discarded, and lysis buffer containing synthetic spike-ins 
(UniSp2, UniSp4 and UniSp5) was added to the pellet. RNA was 
extracted using spin column chromatography (miRCURY RNA 
Isolation Kit, Exiqon). To obtain cDNA, each RNA sample was 
incubated for 60 min at 42°C in the presence of reaction buffer, 
nuclease-free water, enzyme mix and synthesis RNA spike-in 
mix (cel-miR-39-3p and UniSp6) (miRCURY RNA Isolation Kit, 
Exiqon). Reverse transcriptase (RT) was heat-inactivated for 
5 min at 95°C, and the cDNA samples were immediately stored 
at −80°C. Immediately prior to real-time PCR, each cDNA 
sample was thawed and added to a Master Mix working-solution 
containing SYBR Green (Exiqon). Ten microlitres of this mix 
was added to each of the 768 wells of the ready-to-use Human 
microRNA panel I+II, V4.M (Exiqon). Panel I+II contained a 
total of 752 individual miRNA primer sets plus control assays. 
Plates were spun at 1500 × g for 1 min. Plates were run on the 
Applied Biosystems 7900HT Real-Time PCR System (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). Only miRNAs 
detected with Ct <40 were included in the analysis. After 
normalisation to cel-mir-39-3p, as previously described by 
Freischmidt et al,24 cycle threshold (Ct) values were converted 
to linear scale relative to the control group (healthy non-muta-
tion carriers), and Log2 conversion was applied (Exiqon Data 
Analysis Guide for miRCURY GenEx software v 3). For the 
sporadic disease cohort (n=40), CSF was thawed, and cDNA 
was obtained from the exosomal miRNA content as described 
above. For technical validation of the results obtained in the 
GENFI cohort and for the sporadic disease cohort, a Master Mix 
working-solution containing either hsa-204-5p or hsa-miR-632 
PCR primer set (both Exiqon) and SYBR Green (Exiqon) was 
prepared. Master Mix and samples were added to 96-well plates 
and run on the Applied Biosystems Step One Plus Real-Time PCR 
System (Thermo Fisher Scientific). MiRNA expression changes 
were calculated relative to HCs using the 2−ΔΔCt method25 with 
ΔCt=CtmiRNA – Ctreference and 
ΔΔCt=ΔCtpatient or mutation carrier − 
ΔCtcontrol 
pool. UniSp6 spike-in was used as a reference for normalisation. 
RNA and DNA spike-ins showed steady levels across samples 
indicating accurate RT reaction and PCR. Applied Biosystems 
SDS V.2.2.2. software (Thermo Fisher Scientific) and GenEx 6 
(MultiD Analyses, Göteborg, Sweden) were used for miRNA 
expression processing prior to statistical analysis.
statistical analysis
Welch’s t-test was performed and corrected for multiple compar-
isons using the Holm-Sidak method when relative miRNAs 
expression changes passed D’Agostino & Pearson normality 
test. When relative miRNA expression changes calculated as 2−
ΔΔCt were not normally distributed, Mann-Whitney U test was 
performed. Fisher’s exact test was used to detect differences in 
miRNA detection frequency. Correlations between clinical data 
and miRNA expression were calculated using Spearmans’s rank 
order correlation. Receiver operating characteristics (ROC) 
curves and the area under the curve (AUC) were established to 
evaluate the diagnostic value of miRNA expression changes. 
For cross-validation, we used 50% of the dataset to train linear 
models and 50% to validate the results. We then calculated Pear-
son’s bivariate correlation. Statistical analysis was performed 
using GraphPad Prism V.7.01 (La Jolla, California, USA). IBM 
SPSS V.24.0 was used for logistic regression, ROC calculations 
and cross-validation. P values <0.05 were considered significant. 
When the 90% CI included 1, P values were reported as P trend.
Target prediction and gene ontology analysis
Targets of each significantly different miRNA were predicted 
using miRWalk 2.0, which combines information from 12 
existing miRNA-target prediction programs (DIANA-mi-
croTv4.0, DIANA-microT-CDS, miRanda-rel2010, mirBridge, 
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Figure 1 Relative expression of miR-204-5p and miR-632 is lower in symptomatic compared with presymptomatic mutation carriers. MiRNa expression 
was calculated relative to that of healthy non-mutation carriers. Data from individuals with any of the three mutations were grouped, and expression of both 
miR-204-5p and miR-632 was found to be significantly lower in symptomatic compared with presymptomatic individuals (a). Only data from individuals 
with a GRN mutation were grouped, and expression of both miR-204-5p and miR-632 was found to be significantly lower in symptomatic compared 
with presymptomatic individuals (B). Only data from individuals with a C9orf72 mutation were grouped, and expression of miR-204-5p was found to be 
significantly lower in symptomatic compared with presymptomatic individuals (c). Only data from individuals with any of the three mutations and the 
bvFTD phenotype were grouped, and expression of both miR-204-5p and miR-632 was found to be significantly lower in symptomatic compared with 
presymptomatic individuals (D). Welch’s t-tests were corrected for multiple comparisons using the holm-sidak method, *p<0.05, ***p<0.005. Mean and sD 
of mean are shown. C9orf72, chromosome 9 open reading frame 72; GRN, progranulin; bvFTD, behavioural variant FTD.
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miRDB4.0, miRmap, miRNAMap, doRiNA/PicTar2, PITA, 
RNA22v2, RNAhybrid2.1 and Targetscan6.2)26 (online supple-
mentary table 3). Only experimentally validated mRNAs were 
included in further analyses. The KEGG database was used to 
identify target mRNAs in biological pathways ( c2. cp. kegg. v5. 
1. symbols. gmt).27 To assess whether target mRNAs were previ-
ously found highly expressed in the human frontal and temporal 
lobes relative to the entire human brain, we searched the Allen 
Brain Atlas (http://www. brain- map. org).28 The original search 
can be reproduced at http:// human. brain- map. org/ microarray/ 
search/ show? domain1= 4005& domain2= 4009, 4132& 
selected_ donors= 9861, 10021, 12876, 14380, 15496, 15697& 
search_ type= differential. FunRich V.3.0 was used to generate 
Venn diagrams of validated targets found with miRWalk 2.0, the 
KEGG pathway database and the Allen Brain Atlas.
resulTs
exosomal mir-204-5p and mir-632 expression is low in 
genetic FTd
We reasoned that a clinically useful diagnostic biomarker would 
be detectable in healthy individuals and altered in disease. We 
found two miRNAs (miR-204-5p and miR-632) in all exosomal 
CSF samples of healthy non-mutation carriers and an addi-
tional six miRNAs in at least 70% (miR-605-5p, let-7a-5p, 
miR-548a-3p, miR-23b-3p, miR-125b-5p and miR-937-3p) 
(online supplementary figure 1). MiRNA expression in exosomal 
CSF samples from healthy non-mutation carriers was used to 
obtain baseline values for each miRNA. MiRNA expression 
relative to this baseline was compared between presymptomatic 
and symptomatic mutation carriers. No significant expression 
changes were found between healthy non-mutation carriers and 
presymptomatic mutation carriers. Relative expression of both 
miR-204-5p and miR-632 was significantly lower in symptomatic 
compared with presymptomatic mutation carriers (P<0.005 and 
P<0.05) (figure 1A). Relative expression of miR-204-5p was 
significantly lower in symptomatic mutation carriers with 
either GRN or C9orf72 mutations (P<0.05 and P<0.05) 
(figure 1B,C). Relative expression of miR-632 was significantly 
lower in symptomatic compared with presymptomatic mutation 
carriers in the GRN group (P<0.05) but not in the C9orf72 
group (figure 1B,C). With only one symptomatic mutation 
carrier in the MAPT group, statistical analysis was not possible. 
Most symptomatic mutation carriers had been diagnosed with 
bvFTD (80%) (online supplementary table 1). Relative expres-
sion of both miR-204-5p and miR-632 was still significantly 
lower when bvFTD only was compared with presymptomatic 
mutation carriers (P<0.005 and P<0.05) (figure 1D). Tech-
nical validation using individual primer sets showed decrease of 
miR-204-5p and miR-632 similar to the results obtained with 
the miRNA panels, when the relative transcript number was 
compared with the pooled sample of healthy non-mutation 
carriers (online supplementary figure 2A–D). Raw Ct values of 
both miRNAs were significantly higher in symptomatic muta-
tion carriers, indicating decreased expression in symptomatic 
individuals, independent of normalisation (online supplemen-
tary figure 2E). Only one individual was diagnosed with either 
svPPA, nfvPPA or D-NOS; therefore, statistical analysis of these 
clinical phenotypes was not possible. Age was significantly 
different between groups with symptomatic mutations carriers 
being older than presymptomatic mutation carriers (all mutation 
carriers: P<0.0001, GRN mutation carriers: P<0.005, C9orf72 
mutation carriers: P<0.05 and bvFTD: P<0.0001). Notably, 
there was no correlation between miR-204-5p expression and 
age in healthy non-mutation carriers and HCs, and there was a 
modest increase of miR-632 expression with age in these healthy 
individuals (P<0.05) (online supplementary figure 3). When we 
analysed females and males separately, we found a decrease of 
204-5p and miR-632 in symptomatic compared with presymp-
tomatic female mutation carriers (n=25), before correcting for 
multiple comparisons (P<0.005 and P<0.05). The numbers 
of male mutation carriers was smaller (n=13), and comparing 
miR-204-5p and miR-632 between symptomatic and presymp-
tomatic male mutation carriers only revealed a trend towards 
significances, before correction for multiple comparisons 
(P<0.06 and P<0.07) (data not shown). We did not observe a 
Figure 2 ROc curve analysis discriminates symptomatic from 
presymptomatic mutation carriers. MiR-204-5p and miR-632 expression 
can discriminate between presymptomatic and symptomatic individuals 
based on ROc. 90% cI are reported in brackets. Dashed grey lines 
represent miR-204-5p, dotted black lines represent miR-632 and solid 
black lines represent the combination of miR-204-5p and miR-632 
determined by logistic regression. all mutation carriers (a), GRN mutation 
carriers (B) and bvFTD phenotype (c) were analysed separately, *p<0.05, 
**p<0.01, ***p<0.005. #p trend cI includes 1.0. aUc, area under the 
curve; GRN, progranulin; bvFTD, behavioural variant FTD.
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significant change of miR-204-5p or miR-632 relative to disease 
duration or MMSE results in healthy non-mutation carriers, 
presymptomatic or symptomatic individuals (data not shown).
low exosomal mir-204-5p and mir-632 expression 
distinguishes symptomatic from presymptomatic individuals
To assess whether the changes in miR-204-5p and 
miR-632 expression can distinguish symptomatic from 
presymptomatic individuals, we calculated ROC. We found 
that a decrease of miR-204-5p and miR-632 discriminated 
well between presymptomatic and symptomatic individ-
uals. The AUC for miR-204-5p was 0.89 (90% CI 0.79 to 
0.98) (P<0.005), and the AUC for miR-632 was 0.81 (90% 
CI 0.68 to 0.93) (P<0.005). Combination of miR-204-5p 
and miR-632 narrowed the CI and increased the AUC to 
0.93 (90% CI 0.87 to 0.99) (P<0.05) (figure 2A). In the 
GRN group, miR-632 discriminated well between presymp-
tomatic and symptomatic individuals with an AUC of 0.85 
(90% CI 0.71 to 0.99) (P<0.01), and there was a trend 
for miR-204-5p and the combination of miR-204-5p and 
miR-632 (figure 2B). In the C9orf72 group, only three 
individuals were symptomatic, and ROC analysis did not 
yield significant results (data not shown). For patients 
with bvFTD, miR-204-5p and miR-632 discriminated well 
between presymptomatic and symptomatic individuals with 
AUCs of 0.91 (90% CI 0.82 to 0.99) and 0.83 (90% CI 
0.71 to 0.95) (both P<0.005), and there was a trend for 
the combination of miR-204-5p and miR-632 (figure 2C). 
In a cross-validation analysis, low miR-204-5p correlated 
significantly with symptomatic status (Pearson correlation 
r=0.636 and P<0.05 in both the training and validation 
dataset), while low miR-632 did not significantly correlate 
with symptomatic status in our model.
specific exosomal mirnAs are detected less or more 
commonly in FTd
We hypothesised that certain miRNAs would not be 
decreased or increased but undetectable in either health or 
disease. We compared symptomatic mutation carriers (symp-
tomatic) with healthy non-mutation carriers and presymp-
tomatic mutation carriers (healthy) to assess for differences 
between disease and health, regardless of mutation status. 
Comparing the frequency of detected miRNAs between 
symptomatic and healthy participants, we found miR-23b-3p, 
miR-326, miR-877-5p, miR-892a less commonly (P<0.05) 
and miR-708-3p more commonly (P<0.01) in symptom-
atic compared with healthy participants (table 1). When 
we compared presymptomatic with symptomatic muta-
tion carriers, we found miR-30b-5p and miR-373-3p less 
commonly in the GRN group (P<0.05) (table 1). No signif-
icant differences were found between presymptomatic and 
symptomatic carriers of C9orf72 or MAPT mutations.
Figure 3 Relative expression of miR-632 is lower in sporadic FTD 
compared with sporadic aD and hcs. MiRNa expression was calculated 
relative to that of hcs using the 2−ΔΔct method. expression values of 
hcs, sporadic aD and sporadic FTD were compared. expression of miR-
204-5p was similar between groups (a, left), and expression of miR-632 
was significantly lower in FTD using Welch’s t-tests (a, right). MiR-632 
expression can discriminate between FTD and non-FTD (hc and aD) based 
on ROc. 90% cI reported in brackets. Dashed grey line represents hc 
versus FTD, dotted black line represents aD versus FTD and solid black line 
represents the combination of hc and aD determined by logistic regression 
(B). **p<0.01, ***p<0.005, #p trend cI includes 1.0. Mean and sD of 
mean are shown. aUc, area under the curve; aD, alzheimer’s disease; FTD, 
frontotemporal dementia; hc, healthy control.
Table 1 Certain miRNAs were less frequently detected in a subgroup of study participants
mirnA Group
healthy symptomatic
P value Commentdetectable undetectable detectable undetectable
miR-23b-3p All participants (n=49) 20 14 3 12 P<0.05 Less common in symptomatic
miR-326 All participants (n=49) 8 26 0 15 P<0.05 Less common in symptomatic
miR-877-5p All participants (n=49) 14 20 1 14 P<0.05 Less common in symptomatic
miR-892a All participants (n=49) 8 26 0 15 P<0.05 Less common in symptomatic
miR-708-3p All participants (n=49) 21 13 15 0 P<0.01 More common in symptomatic
miR-30b-5p GRN mutation carriers (n=22) 7 4 1 10 P<0.05 Less common in symptomatic
miR-373-3p GRN mutation carriers (n=22) 8 3 2 9 P<0.05 Less common in symptomatic
*P<0.05, **P<0.01.
 The detection frequency of miRNAs was compared between healthy non-mutation carriers and presymptomatic mutation carriers (healthy) and symptomatic mutation carriers 
(symptomatic) using Fisher’s exact test. MiR-23b-3p, miR-326, miR-877-5p and miR-892a were detected less commonly and miR-708-3p more commonly in symptomatic 
compared with presymptomatic mutation carriers and healthy non-mutation carriers. The detection frequency of miRNAs was compared between presymptomatic mutation 
carriers and symptomatic mutation carriers using Fisher’s exact test. MiR-30b-5p and miR-373-3p were detected less commonly in symptomatic compared with presymptomatic 
GRN mutation carriers.
GRN, progranulin.
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expression of exosomal mir-632 is lower in sporadic FTd 
compared with sporadic Ad and hCs
We next sought to validate miR-204-5p and miR-632 as 
biomarker candidates in a cohort of sporadic FTD. We observed 
no significant decrease of miR-204-5p expression in sporadic 
FTD compared with sporadic AD or HCs of similar age 
(figure 3A, left); however, mir-632 was significantly decreased 
in sporadic FTD compared with HCs or patients with AD 
(P<0.005) (figure 3A, right). There was no significant difference 
between FTD phenotypes (bvFTD, bvFTD/ALS, svPPA, nfvPPA/
ALS, svPPA/ALS, nfvPPA) (data not shown). To evaluate the diag-
nostic value of miR-632 in differentiating sporadic FTD from AD 
and HCs, we constructed ROC curves (figure 3B). When FTD 
was compared with all non-FTD (HC and AD), the AUC was 
0.90 (90% CI 0.81 to 0.98) (P<0.005). There was a trend for 
AUC to distinguish FTD from HC or AD separately (figure 3B). 
In a cross-validation analysis, low miR-632 correlated signifi-
cantly with a diagnosis of FTD (Pearson correlation r=0.578 and 
P<0.05 in both the training and validation dataset).
decrease or loss of mirnA may result in disease-relevant 
pathway activation
Since the main function of miRNAs is silencing of mRNA, we 
identified mRNA targeted by miRNAs found downregulated 
(miR-204-5p and miR-632), less commonly (miR-23b-3p, 
miR-326, miR-877-5p, miR-892a, miR-30b-5p and miR-373-3p) 
or more commonly in FTD (miR-708-3p) (online supplementary 
table 3). We found 375 mRNAs targeted by miR-204-5p and 38 
mRNAs targeted by miR-632, including three mRNAs targeted 
by both miRNAs (HRK, KNTC1 and POU2F1) (figure 4A). 
When we compared, this group of target mRNAs with mRNAs 
Figure 4 Venn diagrams of miRNa targets. Overlap of mRNa targeted by miRNas found decreased in symptomatic compared with presymptomatic 
mutation carriers (miR-204-5p and miR-632), mRNas enriched in the human frontal and temporal lobes (frontotemporal) and mRNas implicated in Wnt 
signalling (a). Overlap of mRNa targeted by miRNas less frequently detectable in FTD (miR-23b-3p, miR-326, miR-877-5p, miR-892a, miR-30b-5p and miR-
373-3p), more frequently detected in FTD (miR-708-3p), mRNas enriched in the human frontal and temporal lobes and mRNas implicated in Wnt signalling, 
apoptosis, MapK signalling, endocytosis, notch signalling or neurotrophin signalling (B). Number of validated targets within a pathway are shown in grey 
cells, and % of targets found in each pathway are shown in brackets below. 
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enriched in the human frontal and temporal lobes (Allen Institute, 
http://www. brain- map. org),28 we found HRK, a central medi-
ator of apoptosis,29 to be a potential target of both miR-204-5p 
and miR-632 (figure 4A). Wnt signalling has been implicated as a 
central disease pathway in FTD with GRN mutations.30 31 One of 
the mRNAs targeted by miR-204-5p (FZD8) in the Wnt signalling 
pathway was highly expressed in the human frontal and temporal 
lobes. Each miRNA we found downregulated (miR-204-5p and 
miR-632) or less frequently in FTD (miR-23b-3p, miR-326, 
miR-877-5p, miR-892a, miR-30b-5p and miR-373-3p) targets 
several mRNA enriched in the human frontal and temporal lobes 
(figure 4B). Interestingly, targets of miR-204-5p and of the two 
miRNAs less frequent detected in symptomatic GRN mutation 
carriers (miR-30b-5p and miR-373-3p) were relatively enriched 
in the frontal and temporal lobes (27, 13 and 9 targets). In addi-
tion to Wnt signalling, RNA targets of exosomal miRNAs were 
found in apoptosis, MAPK signalling, endocytosis, notch signal-
ling and neurotrophin signalling (figure 4B).
dIsCussIOn
Discovery of biomarkers for FTD would result in more accu-
rate diagnoses and facilitate early and specific treatment efforts. 
Previous studies indicate altered expression of specific miRNAs 
in the brains of patients affected by neurodegenerative diseases 
including FTD, AD, Parkinson’s disease and Huntington’s 
disease.5 32 33 Galimberti et al34 measured miRNAs in both 
serum and CSF and found both miR-125b and miR-26b signifi-
cantly decreased in AD. More recently, Sørensen et al35 found 
let-7i-5p and miR-15a-5p increased and miR-29c-3p decreased 
in CSF samples from patients with AD. Since disease-relevant 
miRNAs may be enriched within exosomes,17 18 we opted to 
evaluate exosomal miRNA. We found significantly lower expres-
sion of miR-204-5p and miR-632 in symptomatic compared 
with presymptomatic mutation carriers in the genetic FTD 
cohort. While the C9orf72 group followed this trend, most data 
supporting our conclusions come from symptomatic GRN muta-
tion carriers and individuals diagnosed with bvFTD.
In the sporadic disease cohort, miR-204-5p expression was 
not significantly different in FTD compared with AD and HCs, 
suggesting that genetic factors influence miR-204-5p expression. 
However, miR-632 was significantly decreased in sporadic FTD, 
underlining its potential as a diagnostic biomarker candidate for 
both genetic and sporadic FTD. ROC discriminated well between 
FTD and non-FTD (HC and AD). We appreciate that the frequency 
distribution of FTD, AD and HCs in our sample was not necessarily 
representative and that the true sensitivity and specificity of the test 
may be lower in a typical clinical setting.
Using in silico analysis, we found HRK to be a potential 
target of both miR-204-5p and miR-632 in the human frontal 
and temporal lobes. HRK encodes for the apoptosis activator, 
HARAKIRI.29 Since the main function of miRNAs is silencing 
of mRNA, low miR-204-5p and miR-632 could result in patho-
logically increased HRK and apoptosis leading to degenerative 
changes within the frontal and temporal lobes of FTD patients. 
Wnt signalling has been implicated in FTD with GRN muta-
tions,30 31 and targeting the Wnt signalling pathway may emerge 
as a future therapeutic.36 In addition to apoptosis and Wnt 
signalling, mRNA targets were found in other biological path-
ways that have been linked with neurodegeneration and/or FTD 
such as MAPK signalling,37 endocytosis,38 39 notch signalling40 
and neurotrophin signalling.41 42
In summary, we showed exosomal miR-204-5p and miR-632 
to have potential as diagnostic biomarkers for genetic FTD and 
miR-632 also for sporadic FTD. Through in silico target predic-
tion and disease pathway analysis, we found some of these miRNAs 
to target mRNAs involved in pathways previously linked to FTD. 
To our knowledge, none of the miRNAs we found significantly 
altered in CSF exosomes have previously been reported in FTD or 
been implicated in its pathology.5 Since miRNAs are still in their 
infancy, this is not unexpected. We must consider some limitations 
of the current study. We appreciate that sex was not matched in 
all groups. For example, while presymptomatic and symptomatic 
GRN groups contained equal numbers of females and males in 
the respective groups, all symptomatic C9orf72 mutation carriers 
were male, which may have introduced bias. Furthermore, most 
presymptomatic and symptomatic mutation carriers tested positive 
for a mutation in GRN, so our results will have to be confirmed 
in larger cohorts including more patients with C9orf72 and MAPT 
mutations. Ideally, our results will be confirmed in prospective 
studies including cohorts of genetic and sporadic FTD before the 
miRNA expression changes described here would be used in clinical 
practice. For the time being, our findings highlight that exosomal 
miRNAs have potential as diagnostic biomarkers for genetic and 
sporadic FTD.
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